Should Cardiologists Risk-stratify Patients With Atherosclerotic Cardiovascular Disease by Kidney Function? Results From the VERTIS CV Trial Evaluating Efficacy of Ertugliflozin on Cardiovascular and Kidney Outcomes by Baseline Kidney Function Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Cherney, David; Charbonnel, Bernard; Cosentino, Francesco; Pratley, Richard; Dagogo-Jack, Samuel; Shih, Weichung J.; McGuire, Darren K.; Frederich, Robert; Maldonado, Mario; Liu, Jie; Pong, Annpey; Liu, Chih-Chin; Cannon, Christopher P.; VERTIS CV Investigators

authors

Publication Date

  • December 15, 2020

webpage

published in

category

start page

  • E483

end page

  • E483

volume

  • 142

issue

  • 24